← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
University of Sao Paulo Olanzapine Tinnitus Study
Also known as: Olanzapine 5 Mg ORAL TABLET, Olanzapine, Zyprexa, OLZ, Treatment of Tinnitus With Olanzapine, NCT07190482
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 1
Status
Completed
Target Gene
—
Route / Mode
Oral
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
Brazil
Population
adult, tinnitus
Trial IDs
1
Mechanism
Completed randomized crossover Phase 1 study of oral olanzapine 5 mg/day versus placebo in subjective tinnitus.
Indications
Notes
Verified as a completed academic olanzapine tinnitus study. No active commercial tinnitus development program was confirmed in this pass.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT07190482
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidencehistorical-studygeneric-repurposing-study
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2